Log in

Relevant bibliographies by topics / Cosentyx / Journal articles

To see the other types of publications on this topic, follow the link: Cosentyx.

Journal articles on the topic 'Cosentyx'

Author: Grafiati

Published: 3 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 45 journal articles for your research on the topic 'Cosentyx.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chebysheva, S. N., E. S. Zholobova, N. A. Geppe, et al. "Efficacy and safety of secukinumab (Cosentyx) in patients with juvenile psoriatic arthritis." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 70, no. 1 (2025): 75–81. https://doi.org/10.21508/1027-4065-2025-70-1-75-81.

Full text

Abstract:

Psoriatic arthritis is a chronic inflammatory disease of the peripheral joints, spinal joints and entheses, occurring in 10–25% of patients with psoriasis. Juvenile psoriatic arthritis is classified as a subtype of juvenile idiopathic arthritis. Treatment of juvenile psoriatic arthritis is challenging. One of the main difficulties is that the drugs used in adult patients have restrictions for use in pediatric practice, which limits the available therapeutic options. There are few studies assessing the effectiveness and safety of secakinumab therapy in pediatric practice.Objective. To evaluate

APA, Harvard, Vancouver, ISO, and other styles

2

Lee, A. S. W., N. J. Levell, S. N. Shah, K. Gaffney, and M. A. W. Tremelling. "Severe colitis complicating secukinumab (Cosentyx ® ) therapy." Clinical and Experimental Dermatology 45, no. 3 (2020): 344–45. http://dx.doi.org/10.1111/ced.14149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Di Giuseppe, Luis A., Gabriela Buela, María Laura Galimberti, Karina Elena Álvarez, Leonardo G. Garfi, and Sergio A. Terrasa. "Experiencia de un contrato de riesgo compartido basado en resultados para el tratamiento de psoriasis en placa con secukinumab (Cosentyx)." Economía de la Salud 17 (July 2022): 57–64. http://dx.doi.org/10.61679/1703057064.

Full text

Abstract:

Objetivo: Este trabajo busca describir el proceso y analizar los resultados a las 16 semanas de la implementación de un contrato de riesgo compartido basado en resultados (CRCBR) para el tratamiento con secukinumab (Cosentyx) en pacientes con psoriasis en placa. Materiales y métodos: En 2016, el Área de Gestión de Fármacos e Insumos del Plan de Salud (PS) del Hospital Italiano de Buenos Aires desarrolló un CRCBR para la utilización de secukinumab en pacientes adultos con psoriasis en placa moderada a severa que nunca hubieran recibido tratamientos biológicos. Se acordó con Novartis Argentina S

APA, Harvard, Vancouver, ISO, and other styles

4

Lukoviek, Vania, María Arteaga Henríquez, José María Ramírez Conchas, Judit Algarra Sahuquillo, Marcella Markthaler, and Marta García Bustinduy. "18292 Fibrosis-4 index in psoriasis patients treated with methotrexate before cosentyx: A descriptive study." Journal of the American Academy of Dermatology 83, no. 6 (2020): AB209. http://dx.doi.org/10.1016/j.jaad.2020.06.924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sun, Hanxi, Jason Plawinski, Sajanth Subramaniam, et al. "A deep learning approach to private data sharing of medical images using conditional generative adversarial networks (GANs)." PLOS ONE 18, no. 7 (2023): e0280316. http://dx.doi.org/10.1371/journal.pone.0280316.

Full text

Abstract:

Clinical data sharing can facilitate data-driven scientific research, allowing a broader range of questions to be addressed and thereby leading to greater understanding and innovation. However, sharing biomedical data can put sensitive personal information at risk. This is usually addressed by data anonymization, which is a slow and expensive process. An alternative to anonymization is construction of a synthetic dataset that behaves similar to the real clinical data but preserves patient privacy. As part of a collaboration between Novartis and the Oxford Big Data Institute, a synthetic datase

APA, Harvard, Vancouver, ISO, and other styles

6

Darch, K. M., T. L. Holland, and L. J. Spelman. "Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23." Case Reports in Medicine 2020 (July 24, 2020): 1–6. http://dx.doi.org/10.1155/2020/9404505.

Full text

Abstract:

Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. The availability of a range of novel, targeted therapies for their treatment, most notably the availability of biologic agents, has revolutionised management of these conditions and allowed for significant improvements in patient outcomes. Secukinumab (Cosentyx), a fully-human monoclonal antibody that acts by selectively binding to and neutralising the proinflammatory cytokine IL-17A, is used widely for th

APA, Harvard, Vancouver, ISO, and other styles

7

Sluzevich, Jason C., Meera H. Patel, Thais P. Pincelli, Caitlin M. Brumfiel, Mark R. Pittelkow, and Aaron Mangold. "25240 Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris: A single arm, open-label exploratory study." Journal of the American Academy of Dermatology 85, no. 3 (2021): AB55. http://dx.doi.org/10.1016/j.jaad.2021.06.244.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sears, A. V., C. Szlumper, K. W. Liu, C. H. Smith, J. N. W. N. Barker, and A. E. Pink. "Clinical outcomes in patients on secukinumab (Cosentyx® ) within a specialist psoriasis clinic: a single centre, retrospective cohort study." Journal of the European Academy of Dermatology and Venereology 33, no. 2 (2018): e89-e91. http://dx.doi.org/10.1111/jdv.15245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Yao, Feng, Chenguang Wang, Jie Ding, et al. "A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects." Drug Design, Development and Therapy Volume 18 (August 2024): 3891–901. http://dx.doi.org/10.2147/dddt.s470619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Eviatar, T., D. Zisman, M. Lidar, T. Reitblat, A. Balbir-Gurman, and O. Elkayam. "FRI0337 REAL WORLD SECUKINUMAB DRUG-SURVIVAL IN PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 761.1–762. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3729.

Full text

Abstract:

Background:Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes IL-17A. Several prospective randomized control trials have demonstrated the efficacy and safety of secukinumab in PsA, but there is a paucity of real life data in the PsA population.Objectives:To prospectively study secukinumab’s safety, efficacy, and tolerability in the cohort of PsA patients from the Israeli registry of inflammatory diseases.Methods:PsA patients fulfilling the CASPAR criteria from the Israeli registry of inflammatory diseases were included in the analysis, from 201

APA, Harvard, Vancouver, ISO, and other styles

11

Corbett, Mark, Fadi Chehadah, Mousumi Biswas, et al. "Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation." Health Technology Assessment 21, no. 56 (2017): 1–326. http://dx.doi.org/10.3310/hta21560.

Full text

Abstract:

BackgroundSeveral biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA®, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX®, Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA®, UCB

APA, Harvard, Vancouver, ISO, and other styles

12

Su, Q. Y., B. R. Zhao, H. J. Gao, et al. "AB1123 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIASIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1791.1–1792. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4563.

Full text

Abstract:

BackgroundPsoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. The interleukin-(IL-)17 axis plays a vital role in the development of psoriasis. Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively targets IL-17A for the treatment of adult patients with psoriasis[1].ObjectivesThis study aimed to systematically evaluate the efficacy and safety of secukinumab therapy in psoriasis.MethodsEight databases (PubMed, Web of Science, Embase, Cochrane Library, Web of Knowledge, MEDLINE, Clinical Trials.gov, and FDA.gov) were searc

APA, Harvard, Vancouver, ISO, and other styles

13

Memar, Omeed, and Benjamin Caughlin. "Latest Therapeutics in Plaque Psoriasis: A Review." ARC Journal of Dermatolog 3, no. 3 (2018): 1–8. https://doi.org/10.20431/2456-0022.0303003.

Full text

Abstract:

Psoriasis is a common systemic inflammatory syndrome that affects numerous organs. It is most evident on the skin, and hence garners the greatest attention. Historically, the treatments for psoriasis made incremental advancements. Since the immunology of the disease has been better understood and the advent of therapeutic monoclonal antibodies, a flood gate of new therapies has been opened. In this review, we discuss the immunology of psoriasis and the recombinant therapies along with the newest therapies on the horizon. 

APA, Harvard, Vancouver, ISO, and other styles

14

Pavelka, K., A. Kivitz, R. Calheiros, E. Quebe-Fehling, P. Pertel, and R. Blanco. "POS0937 MEASURE 2: SECUKINUMAB PROVIDES RAPID AND SUSTAINED RELIEF FROM KEY CLINICAL SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN TNFi-NAÏVE PATIENTS THROUGH 5 YEARS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 770–71. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2049.

Full text

Abstract:

BackgroundAnkylosing spondylitis (AS) is a chronic, inflammatory disease resulting in debilitating clinical symptoms such as pain (70–83%), stiffness (54–90%) and fatigue (53–62%).1-3 Secukinumab (SEC 150 mg) has demonstrated long-term efficacy across multiple indications and is approved for the treatment of active AS in adults who have had an inadequate response to NSAIDs.4,5ObjectivesThe Phase 3 MEASURE 2 trial (NCT01649375) assessed long-term efficacy, safety and tolerability of SEC in patients (pts) with active AS. This post-hoc analysis was conducted specifically to evaluate long-term eff

APA, Harvard, Vancouver, ISO, and other styles

15

Rutović, Željko. "The Body." In medias res 9, no. 16 (2020): 2499–510. http://dx.doi.org/10.46640/imr.9.16.2.

Full text

Abstract:

The popular media industry of spectacle with instruments of “seduction” produces “voluntary cosent” of man in acceptance, imitation and evaluation of distribution of corporate consumer culture. In this world man plays role beyond his ontological need and self-conscious realization of subject as thinking creature. The aim of this paper is to problematize socio-cultural phenomenology of body transfiguration, impressions and experiences in opticum of consumerist globalization. The new construction of “new” body is modeled on techniques of instrumentalisation, stereotyping and hybridization of nar

APA, Harvard, Vancouver, ISO, and other styles

16

Lebovici, Serge. "La psychosomatique et la recherche." Revue française de psychanalyse o 62, no. 5 (1998): 1465–76. http://dx.doi.org/10.3917/rfp.g1998.62n5.1465.

Full text

Abstract:

Résumé Il a paru utile de souligner l’importance des travaux des premiers psychoso- maticiens qui, après Marty et Fain, ont souligné l’importance des vicissitudes du narcissisme primaire dont Sacha Nacht faisait les gardiens de la vie. Le processus de subjectivation est troublé lorsque les parents ne peuvent investir narcissiquement leur bébé et ce dernier ne peut pas « mailler » son narcissisme primaire. La recherche clinique peut porter sur de tels cas, mais l’appareillage recommandé par les organismes de recherche est difficilement applicable. Il faut préférer la recherche qui porte sur les

APA, Harvard, Vancouver, ISO, and other styles

17

Sajid, S. Saiyad, Vara Alkesh, Bhagora Samir, Parmar Dharitri, and Dixit R. "Evaluation Of The Effect Of Chronic Heavy Smoking By Pulmonary Function Test." International Journal of Basic and Applied Physiology IJBAP 2, no. 1 (2013): 51–56. https://doi.org/10.5281/zenodo.4479225.

Full text

Abstract:

Pulmonary functions are significantly affected by the chronic smoking. Study has done to investigate relationships between heavy cigarette smoking ( 20 cigarettes/bidis per day) and pulmonary function in Adult men. Objective is to find out If Chronic heavy smoking start affecting the lung functions as early 5 years of habit. Method: A cross sectional study on 112 individuals , selected randomly from general population of Ahmedabad city was performed. A thourough history analysis (Height, Weight, BMI), Physical examinations Spirometry were done on all indivudials after explaining them procedure

APA, Harvard, Vancouver, ISO, and other styles

18

Olisova, Olga Yu, Victoria O. Nikuradze, and Maria A. Koroleva. "IL-17A in the treatment of nail psoriasis." Russian Journal of Skin and Venereal Diseases 24, no. 4 (2021): 347–54. http://dx.doi.org/10.17816/dv79481.

Full text

Abstract:

BACKGROUND: Psoriasis is an inflammatory skin disease that significantly worsens the quality of the patients life. With vulgar psoriasis, the most common form of the disease, nail damage is observed in more than 50% of cases. AIMS: To evaluate the efficacy and tolerability of secukinumab in the treatment of nail psoriasis (psoriatic onychodystrophy) in real clinical practice. MATERIALS AND METHODS: The study was carried out on the basis of the Clinic for Skin and Venereal Diseases. V.A. Rakhmanov Sechenov University. The participants were 12 patients diagnosed with psoriasis, aged

APA, Harvard, Vancouver, ISO, and other styles

19

Muhtaruddin, Erwin, Evi Avicenna Agustin, and Nur Rahma Hasanah. "Review of The Completeness of Filling In Informed Consent on Sectio Caesarea Action at Cilegon Hospital in 2023." Journal Of Applied Health Research And Development 5, no. 1 (2024): 1–10. http://dx.doi.org/10.58228/joahrd.v5i1.1.

Full text

Abstract:

At the Cilegon City Hospital, there were several Informed Cosent forms which wereincomplete, especially when filling in the identification of the patient and the person incharge of the patient and authentication of the doctor and the person in charge of thepatient. The purpose of this study was to identify patient identity, authentication andimportant reports and to find out the factors causing the incomplete filling of InformedConsent. This type of research uses quantitative descriptive research. The populationin this study is the object population and the subject population and the sample in

APA, Harvard, Vancouver, ISO, and other styles

20

Zouari, A., J. Ben Thabet, A. Guermazi, et al. "Perceived stress among suspected patients during the COVID-19 outbreak in Tunisia." European Psychiatry 64, S1 (2021): S656—S657. http://dx.doi.org/10.1192/j.eurpsy.2021.1743.

Full text

Abstract:

IntroductionWidespread outbreaks of infectious disease, such as COVID-19, are associated with psychological distress and symptoms of mental illness especially for patients with suggestive symptoms.ObjectivesPredict the prevalence of perceived stress and study associated factors among patients with suspected COVID-19 infection.MethodsA cross sectional study was conducted between April and May 2020. Patients consulting the sorting box at the Hedi Chaker Hospital of Sfax and declared suspect to be infected by COVID-19 were invited to participate in our study after given their cosent. Perceived St

APA, Harvard, Vancouver, ISO, and other styles

21

Aydogan, Gonul, Gonca Keskindemirci, Deniz Tugcu, et al. "Granulocyte Transfusion in Febrile Neutropenia." Blood 126, no. 23 (2015): 4612. http://dx.doi.org/10.1182/blood.v126.23.4612.4612.

Full text

Abstract:

Abstract Background: Over last 30 years cure rates are increasing among oncology patients. As the therapy intensifies, infectious complications become more common. Neutropenia is defined as neutrophil counts of <500/mm³ and it is one of the most frequent and severe complications of pediatric cancer therapy. In 12-17% of patients with febrile neutropenia, there are proven bacteremia and fungal infections. Pediatric oncology patients have a frequency of 30 morbidity and 1% mortality due to infections. Granulocyte transfusions (GTX) were found to be an effective protective and therapeutic stra

APA, Harvard, Vancouver, ISO, and other styles

22

SARKAR, SUHENA, SOUTRIK ROY, BIRUPAKSHA BISWAS, SOUMIKA BISWAS, ISHITA SENGUPTA, and ARIJIT BANERJEE. "Comparative assessment of SHBG and insulin level in newly diagnosed type 2 DM patients and age and gender matched diabetic patients on metformin therapy for 3 months in a tertiary medical college in Eastern India." National Journal of Physiology, Pharmacy and Pharmacology 14, no. 12 (2024): 2543. https://doi.org/10.5455/njppp.2024.v14.i12.8.

Full text

Abstract:

Abstract – Background: Metformin , which is a biguanide is administered in patients with Type 2 Diabetes Mellitus , mainly works on by decreasing the synthesis & subsequent production of glucose in the liver via attenuating the hepatic gluconeogenesis. As Type 2 DM is characterized by insulin resistance & this insulin also inhibits production of sex hormone binding globulin (SHBG) in the liver resulting in increased concentrations of free testosterone , researches done worldwide, showed that metformin therapy improves insulin sensitivity, leading to reduced serum insulin and androgen l

APA, Harvard, Vancouver, ISO, and other styles

23

CDA-AMC. "Secukinumab (Cosentyx)." Canadian Journal of Health Technologies 4, no. 10 (2024). http://dx.doi.org/10.51731/cjht.2024.995.

Full text

Abstract:

It is recommended that Cosentyx be reimbursed by public drug plans for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy only if certain conditions are met. Cosentyx should only be covered to treat patients who have moderate to severe HS (Hurley stage II or III), a total abscess and nodule count of 5 or greater, and lesions in at least 2 separate areas of the body. Additionally, these are patients whose HS did not adequately respond to conventional therapy. Cosentyx should onl

APA, Harvard, Vancouver, ISO, and other styles

24

CDA-AMC. "Secukinumab (Cosentyx)." Canadian Journal of Health Technologies 5, no. 1 (2025). https://doi.org/10.51731/cjht.25.1062.

Full text

Abstract:

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Secukinumab (Cosentyx) 75 mg/0.5 mL, 150 mg/1 mL, and 300 mg/2 mL solution for injection and 150 mg powder for solution for injection. Indication: For the treatment of adult patients with moderate to severe hidraden

APA, Harvard, Vancouver, ISO, and other styles

25

"Cosentyx licence extension." Pharmaceutical Journal, 2015. http://dx.doi.org/10.1211/pj.2015.20200295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Aixue, Wang, Wei Feng, Zhang Huanhuan, M. Xixing та L. Yanling. "Cosentyx alleviates psoriasis‐induced podocyte injury by inhibiting the tlr/nf‐κb signaling pathway". Skin Research and Technology 30, № 2 (2024). http://dx.doi.org/10.1111/srt.13562.

Full text

Abstract:

AbstractBackgroundPathological studies have shown an association between psoriasis and renal podocyte injury, and the specific mechanism of podocyte injury in psoriasis remains unclear, with no effective treatments currently available. This study aimed to investigate the underlying mechanisms of podocyte and epidermal cell injury in psoriasis and evaluate the therapeutic effect of Cosentyx.Materials and methodsA psoriasis‐like mouse model was established using BALB/C mice, and Cosentyx treatment was administered via intraperitoneal injection. Various parameters, including skin lesions, urinary

APA, Harvard, Vancouver, ISO, and other styles

27

Gibson, Ruby S., Prerna Salian, Ashley Beckles, et al. "Treatment of necrobiosis lipoidica with secukinumab (Cosentyx): a case series." International Journal of Dermatology, July 2023. http://dx.doi.org/10.1111/ijd.16780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bhatla, Anjali, Melissa Asmar, and Defne A. Amado. "Multiple streptococcal brain abscesses in a patient taking Secukinumab." Neurology: Clinical Practice, September 8, 2020, 10.1212/CPJ.0000000000000964. http://dx.doi.org/10.1212/cpj.0000000000000964.

Full text

Abstract:

The approval of the IL-17A inhibitor Secukinumab (Cosentyx; Novartis International, King of Prussia, Pennsylvania) was a major advance in psoriasis treatment, with most patients experiencing a 75% reduction in severity1. Known side effects include an increase in minor infections, but no major infectious adverse events and no nervous system involvement1–4, leading to broad use and an increase in clinical trials targeting the IL-17 pathway. Here, we describe a patient on Secukinumab who presented with severe neurologic deficits due to multifocal brain lesions. These were found to be disseminated

APA, Harvard, Vancouver, ISO, and other styles

29

"RETRACTION: Cosentyx Alleviates Psoriasis‐Induced Podocyte Injury by Inhibiting the TLR/NF‐κB Signaling Pathway". Skin Research and Technology 31, № 7 (2025). https://doi.org/10.1111/srt.70213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"After Successful of Tocilizumab Plus Micronutrients in The Treatment of COVID19 Patients; Cosentyx May Be Recommended." International Journal of Pharmaceutical And Phytopharmacological Research 10, no. 4 (2020): 161–68. https://doi.org/10.51847/gz72e_l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bedier, Helbies, Stéphane Isnard, Réjean Thomas, and Jean-Pierre Routy. "Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV." Oxford Medical Case Reports 2023, no. 7 (2023). http://dx.doi.org/10.1093/omcr/omad066.

Full text

Abstract:

Abstract A 65-year-old woman successfully treated for human immunodeficiency virus (HIV) and Hepatitis C virus was diagnosed with porphyria cutanea tarda (PCT) and treated by phlebotomies. She developed extensive psoriatic skin lesions resistant to topical treatments and methotrexate. She then received the anti-interleukin-17 (IL-17) secukinumab (Cosentyx) which improved her psoriatic skin lesions. Unexpectedly, her PCT skin lesions healed, allowing phlebotomy discontinuation over 2 years. Without lesions, the patient decided to discontinue secukinumab, leading to the recurrence of psoriatic a

APA, Harvard, Vancouver, ISO, and other styles

32

Velcicky, Juraj, Estelle Ngo, Matthias R. Bauer, et al. "Thiazole‐based IL‐17 inhibitors discovered by scaffold morphing." ChemMedChem, December 23, 2024. https://doi.org/10.1002/cmdc.202400851.

Full text

Abstract:

The pro‐inflammatory cytokine interleukin‐17A (IL‐17) plays an important role in the body’s defense against bacterial and fungal infections. However, overexpression of IL‐17 has been associated with several diseases, including rheumatoid arthritis, asthma, psoriasis, and even cancer. The role of IL‐17 in psoriasis has been confirmed by clinical use of IL‐17 antibodies, e.g. secukinumab (Cosentyx®). Ongoing research is focused on discovering low molecular weight IL‐17 inhibitors. In this publication, we present thiazole‐based IL‐17 inhibitors discovered through a scaffold‐morphing strategy. Thi

APA, Harvard, Vancouver, ISO, and other styles

33

"P07 Shared pathophysiological pathways indicating treatment success of pityriasis rubra pilaris using anti-psoriatic anti-interleukin-17 therapy: a case report." British Journal of Dermatology 191, Supplement_3 (2024). https://doi.org/10.1093/bjd/ljae360.037.

Full text

Abstract:

Abstract Pityriasis rubra pilaris (PRP) is a rare and severe inflammatory skin disorder characterized by reddish-orange scaly patches with prominent follicular involvement. PRP is classified into six distinct clinical subtypes, one of which is genetic. This genetic subtype arises from a gain-of-function mutation of the CARD14 gene activating nuclear factor-kappa B (NFkB) typically located within the psoriasis susceptibility locus 2 (PSORS2) activating the IL13/IL17A cytokine axis.1 Similar to psoriasis, activation of the Th17/IL-23 inflammatory pathway presents diverse therapeutic opportunitie

APA, Harvard, Vancouver, ISO, and other styles

34

Bautista, Aaron, Marissa Tran, and Abby Tyagi. "Use of Nair in Treating Refractory Palmoplantar Keratoderma: A Case Report." Journal of the Osteopathic Family Physicians of California 04, Spring 2025 (2025). https://doi.org/10.58858/040201.

Full text

Abstract:

Background: Palmoplantar keratoderma (PPK) is a heterogeneous group of disorders characterized by thickened skin on the palms and soles, often resistant to conventional treatments. Managing refractory cases presents a significant challenge, necessitating exploration of alternative therapeutic options. Case Presentation: We report a 65-year-old Hispanic female with long-standing, treatment-resistant PPK. Despite multiple systemic and topical therapies—including Otezla, Acitretin, Cosentyx, and steroids—she experienced minimal symptom relief. In an unconventional attempt at symptom management, s

APA, Harvard, Vancouver, ISO, and other styles

35

Bezerra, Hélen Kaline Farias, Paulo Victor Mendes Penafort, Fábio de Abreu Alves, José Divaldo Prado, and Pablo Agustin Vargas. "First Case Report of Oral Histoplasmosis in a Patient Receiving Secukinumab (Cosentyx®): Opportunistic Infections as Complication of Emerging Immunomodulatory Therapies." Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, April 2025. https://doi.org/10.1016/j.oooo.2025.04.096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Pisal, Dipak S., Yangbing Li, Amit Golding, et al. "Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis." Clinical Pharmacology & Therapeutics, October 16, 2024. http://dx.doi.org/10.1002/cpt.3464.

Full text

Abstract:

On October 6, 2023, the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation and dosage of Cosentyx® (secukinumab), for the treatment of adult patients with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non‐radiographic axial spondyloarthritis (nr‐axSpA) with objective signs of inflammation. Clinical pharmacokinetics (PK), efficacy, and short‐term placebo‐controlled safety data were available from clinical studies (NCT04156620 and NCT04209205) with the to‐be‐marketed IV formulation using a maintenance dosage 3 mg/kg every 4 weeks (q4

APA, Harvard, Vancouver, ISO, and other styles

37

"Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Arthritis, Psoriatic,Psoriasis,Spondylitis, Ankylosing, Date of authorisation: 14/01/2015, Revision: 13, Status: Authorised." Case Medical Research, October 2, 2019. http://dx.doi.org/10.31525/cmr-1d27121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Arthritis, Psoriatic,Psoriasis,Spondylitis, Ankylosing, Date of authorisation: 14/01/2015, Revision: 11, Status: Authorised." Case Medical Research, November 23, 2018. http://dx.doi.org/10.31525/cmr-3996ba.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mallon, Ann-Marie, Dieter A. Häring, Frank Dahlke, et al. "Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis." BMC Medical Research Methodology 21, no. 1 (2021). http://dx.doi.org/10.1186/s12874-021-01409-4.

Full text

Abstract:

Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the latest statistical machine learning technology with an innovative IT platform developed to manage large volumes of anonymised data from numerous data sources and types we plan to identify novel patterns with clinical relevance which cannot be detected by humans alone to identify phenotypes and early predictors of patient disease activity and progress

APA, Harvard, Vancouver, ISO, and other styles

40

Kong, Edward L., and Arash Mostaghimi. "Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology." JAMA Dermatology, July 16, 2025. https://doi.org/10.1001/jamadermatol.2025.2142.

Full text

Abstract:

ImportanceThe rising cost of prescription drugs is a major concern in health care. Specialty medications, particularly biologics, have transformed dermatologic care but are expensive and may be factors in disproportionate growth in spending.ObjectiveTo assess the role of specialty medications in Medicare Part D drug spending among physician dermatologists and dermatology-focused advanced practice clinicians (nurse practitioners and physician assistants) from 2013 to 2022.Design, Setting, and ParticipantsThis economic analysis used Medicare Part D prescriber data on drug prescriptions from 2013

APA, Harvard, Vancouver, ISO, and other styles

41

Huang, Xiang, Hao Peng, Dongcheng Zou, et al. "CoSENT: Consistent Sentence Embedding via Similarity Ranking." IEEE/ACM Transactions on Audio, Speech, and Language Processing, 2024, 1–14. http://dx.doi.org/10.1109/taslp.2024.3402087.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Ding, Junqi, Yan Qiao, and Lingxian Zhang. "Plant disease prescription recommendation based on electronic medical records and sentence embedding retrieval." Plant Methods 19, no. 1 (2023). http://dx.doi.org/10.1186/s13007-023-01070-6.

Full text

Abstract:

Abstract Background In the era of Agri 4.0 and the popularity of Plantwise systems, the availability of Plant Electronic Medical Records has provided opportunities to extract valuable disease information and treatment knowledge. However, developing an effective prescription recommendation method based on these records presents unique challenges, such as inadequate labeling data, lack of structural and linguistic specifications, incorporation of new prescriptions, and consideration of multiple factors in practical situations. Results This study proposes a plant disease prescription recommendati

APA, Harvard, Vancouver, ISO, and other styles

43

Vaseashta, Ashok, J. Irudayaraj, S. Vaseashta, I. Stamatin, and A. Erdem. "Approach To An Interdisciplinary Bionanotechnology Education Program: International Network Perspective." MRS Proceedings 931 (2006). http://dx.doi.org/10.1557/proc-0931-kk05-04.

Full text

Abstract:

ABSTRACTMaterials in reduced dimensions demonstrate size dependence and may exhibit properties different from the bulk. Nanomaterials are a fundamentally and entirely new class of materials with remarkable electrical, optical, and mechanical properties, thus offering unique applications. With a 9.7% increase in FY 2004-05 investments and an expected worldwide labor force shortage, education and training has become a key component of the National Nanotechnology Initiative (NNI). The slow response by the academic community to develop nanotechnology curriculum is evidenced by the small number of

APA, Harvard, Vancouver, ISO, and other styles

44

SARKAR, SUHENA, SOUTRIK ROY, BIRUPAKSHA BISWAS, SOUMIKA BISWAS, ISHITA SENGUPTA, and ARIJIT BANERJEE. "Comparative assessment of SHBG and insulin level in newly diagnosed type 2 DM patients and age and gender matched diabetic patients on metformin therapy for 3 months in a tertiary medical college in Eastern India." National Journal of Physiology, Pharmacy and Pharmacology, 2024, 1. https://doi.org/10.5455/njppp.20240731025825.

Full text

Abstract:

Abstract – Background: Metformin , which is a biguanide is administered in patients with Type 2 Diabetes Mellitus , mainly works on by decreasing the synthesis & subsequent production of glucose in the liver via attenuating the hepatic gluconeogenesis. As Type 2 DM is characterized by insulin resistance & this insulin also inhibits production of sex hormone binding globulin (SHBG) in the liver resulting in increased concentrations of free testosterone , researches done worldwide, showed that metformin therapy improves insulin sensitivity, leading to reduced serum insulin and androgen l

APA, Harvard, Vancouver, ISO, and other styles

45

Зорин, И. В., А. Л. Фроленко, Г. К. Карымова, Д. С. Месяц, and З. Т. Альшеева. "Juvenile idiopathic arthritis: clinical case." Лечащий врач, no. 7-8(26) (August 30, 2023). http://dx.doi.org/10.51793/os.2023.26.8.001.

Full text

Abstract:

Введение. Ювенильный идиопатический артрит — артрит неустановленной природы длительностью более 6 недель, развивающийся у детей не старше 16 лет при исключении другой патологии суставов. Заболеваемость ювенильным идиопатическим артритом составляет от 2 до 16 на 100 тыс. детского населения до 16 лет. Распространенность ювенильного идиопатического артрита в разных странах колеблется от 0,05 до 0,6%. На территории Российской Федерации распространенность ювенильного идиопатического артрита у детей до 18 лет достигает 62,3 на 100 тыс. детского населения, первичная заболеваемость — 16,2 на 100 тыс.,

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!